A comment on: “Survival-Effective prognostic factors of rectal cancer patients receiving neoadjuvant chemoradiotherapy.”

Year 2024, Volume: 1 Issue: 3, 217 - 218, 11.10.2024

Sakarie Mustafe Hidig , Abdirizack Farah Hersi

https://doi.org/10.70058/cjm.1505243

Abstract

Dear Editor,
I would like to share my opinion on the article titled "Survival-effective Prognostic Factors of Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy," published in the Cerasus Medical Journal, Volume 1, Issue 2, pages 117-123, on June 14, 2024. The article was authored by Orhun Uzun et al [1]. Firstly, I want to thank the authors for their contribution to the field. The study's objective was clear: to identify survival-effective prognostic factors in this patient population. As mentioned by the researchers, they utilized a retrospective review of 102 patients who underwent surgery for rectal cancer at a single institution, ultimately including 84 patients in the analysis after applying exclusion criteria. While the study’s objective is well-defined, its design and scope present certain limitations that affect the strength and applicability of its conclusions.

Keywords

Rectal Cancer, Chemoradiotherapy, Prognosis

Ethical Statement

None

Supporting Institution

None

Project Number

Not Applicable

References

• 1. Uzun O, Polat E, Duman M, Gülmez S, et al. Survival-Effective Prognostic Factors of Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy. Cerasus J Med. 2024;1(2):117-123.
• 2. Couwenberg AM, Burbach JPM, van Grevenstein WMU,et al. Effect of Neoadjuvant Therapy and Rectal Surgery on Health-related Quality of Life in Patients With Rectal Cancer During the First 2 Years After Diagnosis. Clin Colorectal Cancer. 2018;17(3):e499-e512. doi:10.1016/j.clcc.2018.03.009
• 3. Paschke S, Jafarov S, Staib L, et al. Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer. Int J Mol Sci. 2018;19(9):2577. Published 2018 Aug 30. doi:10.3390/ijms19092577
• 4. Saito N, Sugito M, Ito M, et al. Oncologic outcome of intersphincteric resection for very low rectal cancer. World J Surg. 2009;33(8):1750-1756. doi:10.1007/s00268-009-0079-2.
• 5. Ogura A, Konishi T, Cunningham C, et al. Neoadjuvant (Chemoradiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer. J Clin Oncol. 2019;37(1):33-43. doi:10.1200/JCO.18.00032